Search

Your search keyword '"Abadia, E."' showing total 30 results

Search Constraints

Start Over You searched for: Author "Abadia, E." Remove constraint Author: "Abadia, E."
30 results on '"Abadia, E."'

Search Results

1. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19

3. Determinants of early triage for hospitalization in MPN patients with COVID-19

5. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance

6. 14-Day, High-Dose Acid Suppression, Non-Bismuth Quadruple Therapies (Hybrid vs. Concomitant) for Helicobacter pylori Infection: A Randomized Trial

7. Fourteen-day, high-dose acid suppression, non-bismuth quadruple therapies ('hybrid' vs. 'concomitant') for Helicobacter pylori eradication: a randomised trial

8. Optimized non-bismuth quadruple therapies cure most patients infected with Helicobacter pylori despite resistance to Clarithromycin and Metronidazole

9. Optimizing multiplex SNP-based data analysis for genotyping of Mycobacterium tuberculosis isolates.

10. Combined species identification, genotyping, and drug resistance detection of Mycobacterium tuberculosis cultures by MLPA on a bead-based array

11. Label-free and reagentless electrochemical detection of PCR fragments using self-assembled quinone derivative monolayer: Application to Mycobacterium tuberculosis

12. The use of microbead-based spoligotyping for Mycobacterium tuberculosis complex to evaluate the quality of the conventional method: providing guidelines for Quality Assurance when working on membranes.

13. Resolving lineage assignation on Mycobacterium tuberculosis clinical isolates classified by spoligotyping with a new high-throughput 3R SNPs based method.

14. OC.02.3 FOURTEEN-DAY, HIGH-DOSE ACID SUPPRESSION, NON-BISMUTH QUADRUPLE THERAPIES (“HYBRID” VS. “CONCOMITANT”) FOR HELICOBACTER PYLORI ERADICATION: A RANDOMISED TRIAL

17. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.

18. Breakthrough infections in MPN-COVID vaccinated patients.

19. Second versus first wave of COVID-19 in patients with MPN.

20. Long-term follow-up of recovered MPN patients with COVID-19.

21. Turkish and Japanese Mycobacterium tuberculosis sublineages share a remote common ancestor.

22. [Evaluation of discriminatory power of molecular epidemiology techniques in Mycobacterium tuberculosis Venezuelan isolates].

23. High-Throughput CRISPR Typing of Mycobacterium tuberculosis Complex and Salmonella enterica Serotype Typhimurium.

24. Optimizing multiplex SNP-based data analysis for genotyping of Mycobacterium tuberculosis isolates.

25. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance.

26. "Spoligoriftyping," a dual-priming-oligonucleotide-based direct-hybridization assay for tuberculosis control with a multianalyte microbead-based hybridization system.

27. The use of microbead-based spoligotyping for Mycobacterium tuberculosis complex to evaluate the quality of the conventional method: providing guidelines for Quality Assurance when working on membranes.

28. Resolving lineage assignation on Mycobacterium tuberculosis clinical isolates classified by spoligotyping with a new high-throughput 3R SNPs based method.

29. Mycobacterium tuberculosis complex CRISPR genotyping: improving efficiency, throughput and discriminative power of 'spoligotyping' with new spacers and a microbead-based hybridization assay.

Catalog

Books, media, physical & digital resources